Read more

May 10, 2023
2 min watch
Save

VIDEO: Neoadjuvant, adjuvant studies show promise in preventing HCC recurrence

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Thomas Marron, MD, PhD, discussed the larger implications of hepatocellular carcinoma treatments presented at American Association for Cancer Research Annual Meeting.

Marron, an associate professor of medicine at Icahn School of Medicine at Mount Sinai, discussed the promise shown by perioperative and neoadjuvant approaches in liver cancer, but advocated continued research into adjuvant therapies as well.

“I think the neoadjuvant setting is really intriguing, and it’s exciting that we have lots of studies to look at both neoadjuvant and adjuvant because we’re finally going to be able to bring down the risk [for] recurrence in this type of cancer, which is significantly increasing globally at an unprecedented rate,” Marron said.